Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T21:17:08.758Z.
Calculation as of: 2026-10-06T21:17:08.758Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 00a42066d9f3872c54bfb6b46d2066e515b5a7a19eafcedb0603fbeaffc1d64d
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Market Cap
$72.32M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$69.61M
EV/EBIT Ratio
N/A
TTM Avg
25.28x
3Y Avg
28.49x
5Y Avg
157.43x
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| MindWalk Holdings Corp. (HYFT) | $72.83M | N/A | N/A | N/A | N/A |
| Hyperfine, Inc. (HYPR)vs › | $73.27M | N/A | N/A | N/A | N/A |
| Verrica Pharmaceuticals Inc. (VRCA)vs › | $72.32M | N/A | N/A | N/A | N/A |
| Gain Therapeutics, Inc. (GANX)vs › | $71.23M | N/A | N/A | N/A | N/A |
| Tiziana Life Sciences Ltd (TLSA)vs › | $70.63M | N/A | N/A | N/A | N/A |
| Pulmonx Corporation (LUNG)vs › | $75.18M | N/A | N/A | N/A | N/A |
| SkinHealth Systems Inc. (SKIN)vs › | $75.95M | N/A | N/A | N/A | N/A |
| Champions Oncology, Inc. (CSBR)vs › | $69.61M | N/A | 25.28x | 28.49x | 157.43x |
| Outset Medical, Inc. (OM)vs › | $76.74M | N/A | N/A | N/A | N/A |
| Spero Therapeutics, Inc. (SPRO)vs › | $68.90M | 3.35x | 7.89x | 4.27x | 4.27x |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
